PODIUM A home device and cloud based software and algorithm for diabetic foot...
PODIUM A home device and cloud based software and algorithm for diabetic foot ulcer monitoring
"There are 60m adults suffering from diabetes in Europe and 3.8m in UK (5m by 2025). Diabetes has a high mortality rate caused mainly by complications (75,000 deaths p.a., of which 24,000 are premature). One life-threatening compl...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto PODIUM
Duración del proyecto: 6 meses
Fecha Inicio: 2018-12-19
Fecha Fin: 2019-06-30
Líder del proyecto
THERMETRIX LTD.
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"There are 60m adults suffering from diabetes in Europe and 3.8m in UK (5m by 2025). Diabetes has a high mortality rate caused mainly by complications (75,000 deaths p.a., of which 24,000 are premature). One life-threatening complication of diabetes is a diabetic foot ulcer (DFU). Studies revealed a 12% to 25% lifetime risk of developing DFU for diabetics, meaning over 9m Europeans (c.456,000 to 1m in UK) might suffer from DFU in their lifetime. A serious consequence of DFU is lower limb amputation; 85% of the amputations in diabetes sufferers are reported after unsuccessful DFU treatment amounting to 290,000–450,000 amputations/year in Europe, at a cost of €2–2.5bn/year.
The PODIUM™ technology is a novel, extremely reliable and highly sensitive solution for the cost-effective diagnosis and monitoring of DFUs through rapid temperature imaging and reliable analysis of thermographs. PODIUM™ will result in increased numbers of prevented DFUs through 10X higher sensitivity than any competitive solutions. A timely response from physicians, facilitated by PODIUM™ could reduce DFU-related amputations and healthcare costs. Thermetrix’s technology will provide a considerable Quality of Life (QoL) improvement for users and enable substantial savings in healthcare even if only a very small percentage would adopt PODIUM™. The global DFU and pressure ulcers market is expected to grow from US$2.8bn in 2015 to US$4.9bn by 2024 (CAGR 6.6%).
The objectives of this project are (1) experiment with the introduction of liquid crystalline cholesteric esters instead of infrared-cameras as detection method (dramatically decreasing the cost of the method); (2) validate the higher efficacy, diagnostic value, convenience and cost-effectiveness of PODIUM™ over conventional approaches; and (3) validate the business model based on ""unit costs plus cloud subscription"" with the aim of generating a ROI of 23:1 based only on European sales only.
"